Your browser doesn't support javascript.
loading
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Van Cutsem, Eric; Joulain, Florence; Hoff, Paulo M; Mitchell, Edith; Ruff, Paul; Lakomý, Radek; Prausová, Jana; Moiseyenko, Vladimir M; van Hazel, Guy; Cunningham, David; Arnold, Dirk; Schmoll, Hans-Joachim; Ten Tije, Albert J; McKendrick, Joseph; Kröning, Hendrik; Humblet, Yves; Grávalos, Cristina; Le-Guennec, Solenn; Andria, Michael; Dochy, Emmanuelle; Vishwanath, Raghu L; Macarulla, Teresa; Tabernero, Josep.
Afiliação
  • Van Cutsem E; Digestive Oncology, University Hospitals Gasthuisberg/Leuven, Leuven, Belgium. Eric.VanCutsem@uzleuven.be.
  • Joulain F; Sanofi, Chilly Mazarin, France.
  • Hoff PM; Centro De Oncologia, Hospital Sirio Libanes, São Paulo, Brazil.
  • Mitchell E; Kimmel Cancer Center at Jefferson, Jefferson University Hospitals, Philadelphia, PA, USA.
  • Ruff P; Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
  • Lakomý R; Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Prausová J; Fakultni nemocnice v Motole, Prague, Czech Republic.
  • Moiseyenko VM; Scientific Research Institute of Oncology n.a. N.N.Petrov, St-Petersburg, Russian Federation.
  • van Hazel G; University of Western Australia, Perth, Western Australia, Australia.
  • Cunningham D; The Royal Marsden Hospital (Surrey), Sutton, Surrey, UK.
  • Arnold D; Department of Medical Oncology, Tumor Biology Center, Freiburg, Germany.
  • Schmoll HJ; Martin Luther University Halle-Wittenberg, Halle, Germany.
  • Ten Tije AJ; Amphia Hospital, Breda, The Netherlands.
  • McKendrick J; Monash University, Melbourne, Victoria, Australia.
  • Kröning H; Schwerpunktpraxis für Hämatologie und Onkologie, Magdeburg, Germany.
  • Humblet Y; St-Luc University Hospital, Brussels, Belgium.
  • Grávalos C; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
  • Le-Guennec S; Sanofi, Vitry-sur-Seine, France.
  • Andria M; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Dochy E; Sanofi-Aventis Belgium, Diegem, Belgium.
  • Vishwanath RL; Sanofi Global Oncology Medical Affairs, Cambridge, MA, USA.
  • Macarulla T; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Target Oncol ; 11(3): 383-400, 2016 06.
Article em En | MEDLINE | ID: mdl-26706237
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organoplatínicos / Proteínas Recombinantes de Fusão / Camptotecina / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Fatores de Crescimento do Endotélio Vascular Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos Organoplatínicos / Proteínas Recombinantes de Fusão / Camptotecina / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Fatores de Crescimento do Endotélio Vascular Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article